Insider buying last 90 days
No open-market insider purchases were filed for ILMN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 16 close
This week's headlines around Illumina center on clinical sequencing demand and product development rather than a single catalyst. At the UBS Global Healthcare Conference, executives pointed to clinical demand and sequencing consumables as central to growth even as research customers face continued grant funding uncertainty. Separately, Illumina advanced its MRD research portfolio, launching an early access program for ultrasensitive duplex sequencing technology aimed at molecular residual disease and tumor evolution research, with reproducible detection of ctDNA at 2.5 parts per million in representative studies.
Illumina closed at $198.00, down 4.4%, with the one-month return at -24.6% against a six-month gain of 39.9% and a one-year gain of 65.1%. The close sits between the 50-day average of $248.62 and the 200-day average of $179.78, reflecting a mixed trend. The GekkoIndex reads 68.2, placing the stock in the Accumulation zone, up 3.8 over five periods. Price sits 22% below Gekko Fair Value of $253.99.
The next earnings date is 4 February 2027, 79 days out, after the last report on 29 October 2026 showed EPS of $1.62 against a $1.36 estimate, though shares reacted -18.3%. Over the last 30 days, one unusual options signal appeared, with call premium of $484,785 against put premium of $750,905. Seasonality over five years shows a 6.8% average 20-day return from this point, positive in 4 of those years. Analyst consensus across 17 firms includes 8 buy, 6 hold and 3 sell ratings, with a consensus target of $261.45.
Written by AI from the Nov 16, 2026 close and checked automatically against the figures on this page.
Illumina scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Averages disagree
Close $198.00 sits between the 50-day ($248.62) and 200-day ($179.78) averages, or the averages disagree.
See the chart68.2, Accumulation
Reading 68.2 is in the Accumulation zone.
See the GekkoIndex22.0% below
Price is 22% below Gekko Fair Value (more than 5% below).
See fair valueLeans bearish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 79 days
Next report Feb 4, 2027, 79 days away — outside a typical 20-trading-day hold.
See earnings+8.5% on average
From this point in the calendar, the next 20 trading days averaged +8.5% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Illumina closed at $198.00 on Nov 16, 2026, +65.1% over the past year, inside a 52-week range of $112.65 to $309.35.
Use the left and right arrow keys to read daily values.
Put ILMN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Illumina builds tools that read and interpret DNA, centering on sequencing and array technology. Its systems help laboratories and clinics turn genetic material into usable insight, supporting work in areas such as life sciences research, cancer diagnostics, reproductive health, and agriculture, along with newer areas of genomic study. The company is particularly associated with the instruments and related supplies that make this kind of large-scale genetic analysis possible.
Revenue comes from selling sequencing and genotyping instruments alongside the consumables they require, plus related services such as equipment servicing, licensing and development partnerships, and cancer screening tests. Customers include research institutions, universities, government and hospital laboratories, drug and biotech developers, diagnostic companies, and firms in consumer genomics. Illumina reaches these customers both by selling to them directly, across North America, Europe, Latin America and the Asia-Pacific, and through distributor partners who cover additional regions including the Middle East and Africa.
The company was founded in 1998 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker ILMN.
Illumina’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.2, in the Accumulation zone, up 3.8 points over five sessions.
Up 3.8 points over five sessions.
Reading for Nov 16, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | −1.4% | −4.0% | ||
| Accumulation (current zone) | 172 | +0.5% | −1.0% | ||
| Neutral | 424 | +0.9% | +4.6% | ||
| Distribution | 58 | −0.1% | +3.2% | ||
| Selling | 1 | Too few readings yet | |||
Average ILMN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +1.9% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Illumina trades 22.0% below Gekko Fair Value of $253.75, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Illumina shares are worth, recalculated every trading day.
$253.75
Gekko Fair Value, Nov 17, 2026
22.0% Undervalued
At the end of Aug 2026 the price was 8.2% above the estimate.
No open-market insider purchases were filed for Illumina, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ILMN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ILMN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Illumina has been buying back its own shares.
From company filings.
1signal, 39% of the flagged premium in calls.
Latest: Bearish flow on Nov 3, $1.24M in unusual premium.
0of the funds Gekko tracks hold ILMN.
Illumina reports on Feb 4, 2027, after the close (79 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 4, 2027
Expected after the close, 79 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $1.62 est $1.36 | $1.17B est $1.15B | −18.3% |
| Jul 30, 2026 | $1.31 est $1.23 | $1.16B est $1.13B | +5.3% |
| Apr 30, 2026 | $1.15 est $1.07 | $1.09B est $1.07B | +12.8% |
| Feb 5, 2026 | $1.35 est $1.22 | $1.16B est $1.12B | −10.8% |
| Oct 30, 2025 | $1.34 est $1.17 | $1.08B est $1.07B | +30.0% |
| Jul 31, 2025 | $1.19 est $1.02 | $1.06B est $1.06B | −11.3% |
| May 8, 2025 | $0.97 est $0.94 | $1.04B est $1.03B | −0.8% |
| Feb 6, 2025 | $0.86 est $0.92 | $1.10B est $1.07B | −10.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Illumina is $261.45, +32.0% from the last close, from 17 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 17 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Bernstein | — | — |
| Nov 5 | Robert W. Baird | $236 | +19.2% |
| Nov 2 | Freedom Capital Markets | $200 | +1.0% |
| Nov 2 | Citi | $210 | +6.1% |
| Oct 30 | Stifel Nicolaus | $300 | +51.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 17, Illumina averaged +8.5% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.7% | 3 of 5 |
| Next 10 trading days | +5.4% | 3 of 5 |
| Next 15 trading days | +6.8% | 3 of 5 |
| Next 20 trading days | +8.5% | 4 of 5 |
| Next 30 trading days | +7.3% | 3 of 5 |
For scale, ILMN’s typical 20-trading-day move in either direction is about 8.2%.
Illumina’s market cap is $29.94B, with a P/E ratio of 35.6 and revenue of $4.54B over the last twelve months.
3 headlines about Illumina from the past week, newest first, each linking to the publisher.
Illumina’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 13.7% above |
| ABTAbbott Laboratories | Neutral | 11.1% below |
| DHRDanaher | Neutral | 3.9% above |
| ISRGIntuitive Surgical | Neutral | 16.1% above |
| MDTMedtronic | Neutral | 13.6% below |
| SYKStryker | Neutral | 0.6% above |
A peer links to its own page where one exists.
Illumina’s market cap is $29.94B at the Nov 16, 2026 close of $198.00, with 151.2M shares outstanding. The shares trade on a P/E ratio of 35.6.
The consensus analyst 12-month price target for Illumina is $261.45, +32.0% from the last close. Of the 17 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 3 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Illumina is undervalued: the Nov 16, 2026 close of $198.00 is 22.0% below Gekko Fair Value of $253.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Illumina is expected to report on Feb 4, 2027, after the market closes (79 days away). Analysts expect earnings of $1.52 per share on revenue of $1.23B. Illumina beat the earnings estimate in 7 of its last 8 reports, moving 12.5% on average across the report.
Illumina’s 52-week high is $309.35 and its 52-week low is $112.65; it closed at $198.00 on Nov 16, 2026, +65.1% over the past year. Over the last five years the shares peaked at $415.94 on Jan 12, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Illumina over the last 30 days, with $485K of flagged premium in calls and $751K in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.24M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,476 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.